Results 111 to 120 of about 81,293 (260)

Fenfluramine in SCN1A‐related GEFS+: A multicenter observational study on efficacy, EEG improvement, and tolerability

Epilepsia Open, EarlyView.
Abstract The SCN1A gene is implicated in a broad spectrum of epilepsy phenotypes, ranging from self‐limited genetic epilepsy with febrile seizures plus (GEFS+) to severe developmental and epileptic encephalopathies such as Dravet syndrome (DS). While fenfluramine (FFA) has demonstrated strong efficacy in DS, its role in SCN1A‐related epilepsies beyond ...
Giovanni B. Dell'Isola, Alice Muda, Lucio Giordano, Renzo Guerrini, Alessandra Boncristiano, Nicola Pietrafusa, Maria Polselli, Francesca Bisulli, Francesca Ragona, Antonella Riva, Pasquale Striano, Domenica Immacolata Battaglia, Federico Vigevano   +12 more
wiley   +1 more source

Accumulation and Subcellular Distribution Patterns of Carbamazepine in Hydroponic Vegetables

Biology
Pharmaceutical and Personal Care Products (PPCPs), such as carbamazepine, enter the food chain through wastewater irrigation, posing risks to ecosystems and human health.
Sihan Yao, Yan Chen, Nan Zheng, Ting Chen, Sufen Zhang, Zhiyang Yu, Haiyan Wang   +6 more
doaj   +1 more source

Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open‐label prospective study

Epilepsia Open, EarlyView.
Abstract Objective CDKL5 deficiency disorder (CDD) is an early‐onset developmental and epileptic encephalopathy characterized by frequent drug‐resistant seizures, cerebral visual impairment, motor dysfunction, and sleep and gastrointestinal disturbances.
Marco Perulli, Alessia De Gioia, Federica Ruggiero, Federica Ascione, Chiara Porto, Elisa Musto, Valentina Massaroni, Maria Picilli, Maria Luigia Gambardella, Michela Quintiliani, Ilaria Contaldo, Chiara Veredice, Domenica Immacolata Battaglia   +12 more
wiley   +1 more source

Study of efficacy of the combination of carbamazepine with nootropics on cognitive processes in epilepsy [PDF]

Medičnì Perspektivi, 2013
The authors studied the efficacy of combination of carbamazepine with nootropic drugs on cognitive processes in patients with epilepsy in experiment in order to reduce the side effects of anticonvulsant therapy.
Ivanov A.V., Opryshko V.I.
doaj  

CARBAMAZEPINE INDUCED OSTEOPENIA IN BIPOLAR DISORDER: A CASE REPORT

Psychiatry and Clinical Psychopharmacology, 2021
Carbamazepine is an effective anticonvulsant drug in treatment of mood disorders. Alterations in bone metabolism have been reported with carbamazepine.
İbrahim Eren, İkbal Çivi İnanlı
doaj  

Cognitive safety under epicranial cortex stimulation of the epileptic focus

Epilepsia Open, EarlyView.
Abstract Epicranial focal cortex stimulation (FCS) is a new CE‐certified treatment for pharmacoresistant focal epilepsy. In a multicenter observational trial, we report cognitive tolerability in 11 patients with pharmacoresistant epilepsy undergoing epicranial focal cortex stimulation (eFCS) over the predominant seizure focus (left temporal (N = 4 ...
Kathrin Wagner, Iris Gorny, Julia Kustermann, Jessika Paula Losacker, Birgitta Metternich, Julia Berg, Bastian E. A. Sajonz, Volker Arnd Coenen, Elisabeth Kaufmann, Susanne Knake, Andreas Schulze‐Bonhage   +10 more
wiley   +1 more source

Sialidosis type I: How to alleviate disabling myoclonic seizures?—A multicenter analysis of eight cases and review of the literature

Epilepsia Open, EarlyView.
Abstract Objective Sialidosis type I (ST‐1) is an autosomal‐recessive, very rare, progressive lysosomal storage disorder caused by pathogenic variants in NEU1. It is clinically characterized by progressive ataxia, myoclonic seizures (MS), bilateral tonic–clonic seizures (BTCS), and distinctive ophthalmological findings.
Janina Gburek‐Augustat, I‐Chun Lee, Marica Rubino, Vehap Topçu, Melissa Chavez‐Castillo, Shao Ching Tu, Marwan Shinawi, Isabel Alfradique‐Dunham, Manouela Valtcheva, Astrid Adarmes‐Gómez, Daniel Macias‐Garcia, Laura Laura Muñoz‐Delgado, Silvia Jesús, Pablo Mir, Andreas Merkenschlager, Antonietta Coppola   +15 more
wiley   +1 more source

Clinical Evaluation of Drug-Drug Interactions With Aficamten. [PDF]

Clin Transl Sci
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in ...
Maharao N, Xu D, Divanji P, Simkins TJ, Li J, Dumitrescu C, Solanki P, Griffith A, Heitner SB, Kupfer S, German P, Lutz JD.   +11 more
europepmc   +2 more sources

Cilostazol geno-protective effects mitigate carbamazepine-induced genotoxicity in human cultured blood lymphocytes

Toxicology Reports
Background: Carbamazepine is one of the most widely used antiepileptic drugs. Carbamazepine has been shown to be toxic to cells. Cilostazol, an antiplatelet agent, has known antioxidant, antiproliferative, anti-inflammatory, and anti-tumor effects ...
Enaam M. Al Momany, Abeer M. Rababa’h, Karem H. Alzoubi, Omar F. Khabour   +3 more
doaj   +1 more source

Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome

JPGN Reports, EarlyView.
Abstract We present a novel case of gastrointestinal strictures in a young girl with Satoyoshi syndrome (SS), highlighting multi‐system features of alopecia universalis, painful muscle cramps with dystonia, aberrant growth velocity, and skeletal abnormalities.
Katherine (Tusia) Pohoreski, Gary Galante, Kiera Pajunen, Marie‐Anne Brundler, Samarjeet Bhandal, Iwona Wrobel   +5 more
wiley   +1 more source